Compare OBK & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OBK | AUPH |
|---|---|---|
| Founded | 1912 | 1993 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 2.1B |
| IPO Year | 2018 | 2014 |
| Metric | OBK | AUPH |
|---|---|---|
| Price | $54.26 | $16.11 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 4 |
| Target Price | ★ $46.67 | $17.25 |
| AVG Volume (30 Days) | 149.9K | ★ 921.0K |
| Earning Date | 04-22-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.13% | N/A |
| EPS Growth | N/A | ★ 5075.00 |
| EPS | ★ 1.97 | 0.53 |
| Revenue | N/A | ★ $283,055,000.00 |
| Revenue This Year | $26.43 | $17.54 |
| Revenue Next Year | $5.79 | $15.74 |
| P/E Ratio | ★ $27.22 | $30.66 |
| Revenue Growth | N/A | ★ 20.38 |
| 52 Week Low | $32.13 | $10.34 |
| 52 Week High | $55.57 | $19.25 |
| Indicator | OBK | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 54.39 | 50.24 |
| Support Level | $52.46 | $15.55 |
| Resistance Level | $55.29 | $16.40 |
| Average True Range (ATR) | 0.84 | 0.38 |
| MACD | 0.02 | -0.04 |
| Stochastic Oscillator | 63.20 | 13.95 |
Origin Bancorp Inc is a financial holding company that provides personalized, relationship banking to businesses, municipalities, and personal clients in the communities it serves. The company offers a broad range of financial services and operates more than 56 locations in Dallas/Fort Worth, East Texas, Houston, North Louisiana, Mississippi, South Alabama, and the Florida Panhandle. It also provides insurance agency products and services through its wholly owned insurance agency subsidiary. The company operates in one business segment, community banking, and is mainly engaged in attracting deposits from individuals and businesses and using these deposits and borrowed funds to originate commercial, residential mortgage, construction, and consumer loans.
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.